Caribou Biosciences Stock Soars 8.83% After Earnings — Liquidation Remains Among Its Options
The cell-therapy developer is exploring strategic alternatives after an October restructuring and difficulty raising capital.
Caribou Biosciences, which develops gene-edited cell therapies for blood cancers, soared 8.83% to $0.45 at Friday's close, adding $4 million in market value. The gain followed Thursday's earnings release, which showed a smaller quarterly loss but lower revenue and cash reserves.
A Rebound After A Steep Retreat
Friday's advance was CRBU's largest one-day gain since October 20, leaving the company with a market value of $48.24 million at Friday's close.
The stock entered the session down 74% for the year at Thursday's close, while the S&P 500 had gained 8%. CRBU had also lost 65% over the previous month.
Caribou's third-quarter loss narrowed from $27.5 million a year earlier to $26.6 million. Cash and investments stood at $94.8 million, versus $142.8 million at year-end.
Liquidation Is Among The Options
Caribou is exploring strategic alternatives that could include a merger, transactions involving its assets or liquidation. Those are possible paths, rather than a completed transaction or a decision to liquidate.
The board approved an October operational restructuring, citing difficulties securing capital for the company's cell therapies.
Two Treatments Still In Trials
Caribou's development work uses chRDNA, its CRISPR genome-editing technology, to create CAR-T cell therapies. Healthy donors supply the cells, allowing treatments to be prepared in advance instead of being made from each patient's cells.
Its clinical candidates are vispa-cel, targeting CD19 in relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, targeting BCMA in relapsed or refractory multiple myeloma. Vispa-cel trials operate in the United States, Australia and Israel.
In April 2025, Caribou eliminated 47 jobs, about 32% of its workforce, to concentrate on those two candidates. The company remains a clinical-stage business with no products approved for sale.
Caribou's smaller quarterly loss leaves it with development programs still in trials and a strategic review whose possible outcomes include liquidation.
Sources
- Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Beats Revenue Estimates — Yahoo Finance
- Caribou Biosciences Inc. : Articles :: Law360 — law360.com
- Castle Biosciences, Inc. (CSTL) Reports Q3 Loss, Beats Revenue Estimates — Yahoo Finance
- Document — sec.gov
- The company's filing (Caribou Biosciences) — SEC filing
- Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Beats Revenue Estimates — Zacks Investment Research
- Caribou Biosciences — Form 10-Q for the quarter ended 2026-09-30 (quarterly results) — SEC EDGAR